Latest & greatest articles for prostate cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on prostate cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on prostate cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for prostate cancer

801. Brachytherapy in early localized prostate cancer

Brachytherapy in early localized prostate cancer Brachytherapy in early localized prostate cancer Brachytherapy in early localized prostate cancer Comite d' Evaluation et de Diffusion des Innovations Technologiques Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Comite d' Evaluation et de Diffusion des Innovations Technologiques (...) . Brachytherapy in early localized prostate cancer. Paris: Comite d´Evaluation et de Diffusion des Innovations Technologiques (CEDIT). 01.06. 2001 Authors' objectives This report aims to assess the wider application of brachytherapy in the treatment of forms of early localized prostate cancer. Authors' conclusions The CEDIT is of the opinion that there are too many reservations regarding brachytherapy as a treatment for early localized prostate cancer in terms of exact indications, methodology, effectiveness

Health Technology Assessment (HTA) Database.2001

803. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer.

Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. 11575286 2001 09 17 2001 10 04 2013 11 21 0028-4793 345 13 2001 Sep 27 The New England journal of medicine N. Engl. J. Med. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. 948-55 Treatment with a gonadotropin-releasing hormone agonist decreases bone mineral density and increases the risk of fracture in men with prostate cancer. We conducted a controlled study (...) of the prevention of osteoporosis in men undergoing treatment with a gonadotropin-releasing hormone agonist. In a 48-week, open-label study, we randomly assigned 47 men with advanced or recurrent prostate cancer and no bone metastases to receive either leuprolide alone or leuprolide and pamidronate (60 mg intravenously every 12 weeks). Bone mineral density of the lumbar spine and the proximal femur was measured by dual-energy x-ray absorptiometry. Trabecular bone mineral density of the lumbar spine was measured

NEJM2001

804. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials.

Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Prostate Cancer Trialists' Collaborative Group Authors' objectives To determine the effect on survival of maximum androgen blockade (MAB) compared with androgen suppression (AS) alone. Searching Electronic databases (...) , trial registers, meeting abstracts and reference lists were searched. Investigators, trial groups and pharmaceutical companies were contacted (see Other Publications of Related Interest no.1). A secretariat and collaborative group (The Prostate Cancer Trialists' Collaborative Group) was established to identify trials and undertake the meta-analysis. Study selection Study designs of evaluations included in the review The review included individual patient data (IPD) from randomised controlled trials

DARE.2000

805. Using the free-to-total prostate-specific antigen ratio to detect prostate cancer in men with nonspecific elevations of prostate-specific antigen levels

Using the free-to-total prostate-specific antigen ratio to detect prostate cancer in men with nonspecific elevations of prostate-specific antigen levels Using the free-to-total prostate-specific antigen ratio to detect prostate cancer in men with nonspecific elevations of prostate-specific antigen levels Using the free-to-total prostate-specific antigen ratio to detect prostate cancer in men with nonspecific elevations of prostate-specific antigen levels Hoffman R M, Clanon D L, Littenberg B (...) , Frank J J, Peirce J C Authors' objectives To determine whether the free-to-total prostate-specific antigen (PSA) ratio improved the diagnostic accuracy of non-specific PSA results. Searching MEDLINE was searched from January 1986 to July 1997 for publications in the English language. The search used a combination of the MeSH terms 'prostate-specific antigen' and 'prostatic neoplasm' and then linked them with 'alpha-1-antichymotrypsin' or with 'free' or 'gamma-semiprotein'. The bibliographies

DARE.2000

806. Cost-effectiveness of androgen suppression therapies in advanced prostate cancer

Cost-effectiveness of androgen suppression therapies in advanced prostate cancer Cost-effectiveness of androgen suppression therapies in advanced prostate cancer Cost-effectiveness of androgen suppression therapies in advanced prostate cancer Bayoumi A M, Brown A D, Garber A M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed (...) by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Six androgen suppression therapies for advanced prostate cancer were examined. These were diethylstilbestrol (DES), bilateral orchiectomy, a nonsteroidal antiandrogen (NSAA; nilutamide), a luteinising hormone-releasing hormone (LHRH) agonist (goserelin), and two combined androgen blockade strategies (NSAA with a LHRH agonist, and NSAA with orchiectomy). Type of intervention Palliative care

NHS Economic Evaluation Database.2000

807. Prostate cancer staging: should MR imaging be used? A decision analytic approach

Prostate cancer staging: should MR imaging be used? A decision analytic approach Prostate cancer staging: should MR imaging be used? A decision analytic approach Prostate cancer staging: should MR imaging be used? A decision analytic approach Jager G J, Severens J L, Thornbury J R, de la Rosette J J, Ruijs S H, Barentsz J O Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods (...) , the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of magnetic resonance (MR) imaging for preoperative staging of prostate cancer. Type of intervention Diagnosis. Economic study type Cost-effectiveness analysis; cost-utility analysis. Study population The study involved 65-year-old patients suspected of having prostate cancer. Setting The setting was hospital. The economic study was carried out

NHS Economic Evaluation Database.2000

808. Follow-up of prostate cancer patients by on-demand contacts with a specialist nurse: a randomized study

Follow-up of prostate cancer patients by on-demand contacts with a specialist nurse: a randomized study Follow-up of prostate cancer patients by on-demand contacts with a specialist nurse: a randomized study Follow-up of prostate cancer patients by on-demand contacts with a specialist nurse: a randomized study Helgesen F, Andersson S O, Gustafsson O, Varenhorst E, Goben B, Carnock S, Sehlstedt L, Carlsson P, Holmberg L, Johansson J E Record Status This is a critical abstract of an economic (...) evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology On-demand follow-up of prostate cancer patients by a specialist nurse was compared to traditional follow-up by a urologist. Type of intervention Treatment. Economic study type Cost-effectiveness analysis (cost-consequences analysis). Study

NHS Economic Evaluation Database.2000

809. Contrasting costs of a prostate cancer educational program by income

Contrasting costs of a prostate cancer educational program by income Contrasting costs of a prostate cancer educational program by income Contrasting costs of a prostate cancer educational program by income Weinrich S P, Weinrich M, Ellison G, Hudson J, Reeder G, Weissbecker I Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed (...) by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of two alternative educational interventions, oriented to inform the risks and benefits of prostate cancer screening. There were followed by screening, using a digital rectal examination (DRE) and/or drawing of blood for a prostate-specific antigen (PSA) test, and a biopsy for those men with abnormal results. The core of the educational interventions included a slide-tape presentation

NHS Economic Evaluation Database.2000

810. Brachytherapy for the treatment of prostate cancer

Brachytherapy for the treatment of prostate cancer Brachytherapy for the treatment of prostate cancer Brachytherapy for the treatment of prostate cancer Medical Services Advisory Committee Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Medical Services Advisory Committee. Brachytherapy for the treatment of prostate cancer. Canberra (...) : Medical Services Advisory Committee (MSAC) 2000: 45 Authors' objectives This report aims to assess the effectiveness of brachytherapy for prostate cancer. Authors' conclusions MSAC recommends that from the evidence pertaining to brachytherapy for the treatment of prostate cancer, interim public funding should be supported for patients with prostate cancer: - at clinical stages T1, T2a or T2b, with Gleason Scores of less than or equal to 6, prostate specific antigen (PSA) of less than or equal to 10 ng

Health Technology Assessment (HTA) Database.2000

811. Brachytherapy for prostate cancer

Brachytherapy for prostate cancer Brachytherapy for prostate cancer Brachytherapy for prostate cancer Oliva G Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Oliva G. Brachytherapy for prostate cancer. Barcelona: Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA). 2000 Authors' objectives To assess (...) the available evidence on the effectiveness of brachytherapy for prostate cancer. Authors' conclusions The intermediate short-term results of brachytherapy (biochemical control levels and disease-free survival) for patients selected with a low risk of extraprostatic progression seem to be comparable to those of other therapeutic options, such as prostatectomy and external radiotherapy. There are no long-term data available, despite the fact that the results of a sample (n=77) followed up for 12 years were

Health Technology Assessment (HTA) Database.2000

812. Brachytherapy and prostate cancer

Brachytherapy and prostate cancer Brachytherapy and prostate cancer Brachytherapy and prostate cancer Conseil d'Evaluation des Technologies de la Sante du Quebec Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Conseil d'Evaluation des Technologies de la Sante du Quebec. Brachytherapy and prostate cancer. Montreal: Conseil d'Evaluation des (...) Technologies de la Sante du Quebec (CETS). CETS 99-5 RF. 2000 Authors' objectives This study aims summarise the available evidence on the use of brachytherapy in the treatment of prostate cancer. It summarises the evidence of brachytherapy's intended and unintended effects and compares these to treatments in current use. Authors' conclusions This report concludes that the evidence is too weak to demonstrate either greater efficacy of brachytherapy compared to other treatments or better cost-effectiveness

Health Technology Assessment (HTA) Database.2000

813. Brachytherapy for prostate cancer

Brachytherapy for prostate cancer Brachytherapy for prostate cancer We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Swedish Agency for Health Technology Assessment and Assessment of Social Services Brachytherapy for prostate cancer Share: Reading time approx. 4 minutes This document was published more than 2 years ago. The nature of the evidence may have changed. Findings by SBU Alert This is a translation of version 1 (...) , published on February 2, 2000. The latest version of this report is not available in English. Brachytherapy is not widely used in Sweden to treat localized prostate cancer. This treatment method has been available for some time, but recent advancements in technology are leading to increased utilization. Findings from isolated, uncontrolled studies of high dose rate brachytherapy in combination with external beam radiotherapy suggest some improvement in treatment outcomes. However, prospective

Swedish Council on Technology Assessement2000

814. Maximal androgen blockade for advanced prostate cancer.

Maximal androgen blockade for advanced prostate cancer. OBJECTIVES: This systematic review assessed the effect of maximal androgen blockade (MAB) on survival when compared to castration (medical or surgical) alone for patients with advanced prostate cancer. SEARCH STRATEGY: Randomized controlled trials were searched in general and specialized databases (MEDLINE, EMBASE, Cancerlit, Cochrane Library, VA Cochrane Prostate Disease register) and by reviewing bibliographies. SELECTION CRITERIA: All (...) published randomized trials were eligible for inclusion provided they (1) randomized men with advanced prostate cancer to receive a non-steroidal anti-androgen (NSAA) medication in addition to castration (medical or surgical) or to castration alone, and (2) reported overall survival, progression-free survival, cancer-specific survival, and/or adverse events. Eligibility was assessed by two independent reviewers. DATA COLLECTION AND ANALYSIS: Information on patients, interventions, and outcomes were

Cochrane2000

815. The diagnostic value of digital rectal examination in primary care screening for prostate cancer: a meta-analysis

The diagnostic value of digital rectal examination in primary care screening for prostate cancer: a meta-analysis The diagnostic value of digital rectal examination in primary care screening for prostate cancer: a meta-analysis The diagnostic value of digital rectal examination in primary care screening for prostate cancer: a meta-analysis Hoogendam A, Buntinx F, de Vet H C Authors' objectives To systematically review the literature in order to examine the diagnostic value of digital rectal (...) examination (DRE) for the diagnosis of prostate cancer in a primary care setting. Searching MEDLINE was searched from 1993 to 1995. FAMLI, a specialist family practice database, was also searched but no search dates were given. Some general practice journals were handsearched. The reference lists of the included studies were checked for additional citations. No language restrictions were reported. Study selection Study designs of evaluations included in the review Diagnostic accuracy studies were eligible

DARE.1999

816. The role of androgen deprivation in the definitive management of clinically localized prostate cancer treated with radiation therapy

The role of androgen deprivation in the definitive management of clinically localized prostate cancer treated with radiation therapy The role of androgen deprivation in the definitive management of clinically localized prostate cancer treated with radiation therapy The role of androgen deprivation in the definitive management of clinically localized prostate cancer treated with radiation therapy Vicini F A, Kini V R, Spencer W, Diokno A, Martinez A A Authors' objectives To determine (...) the efficacy of androgen deprivation given in combination with radiotherapy for localised prostate cancer and the patients most suitable for its application. Searching MEDLINE was searched from January 1980 to September 1998 for English language studies. The keywords employed were stated in the paper. Study selection Study designs of evaluations included in the review Studies on prostate cancer treatment employing radiotherapy combined with androgen deprivation were included. Study designs include both

DARE.1999

817. Brachytherapy for prostate cancer

Brachytherapy for prostate cancer Brachytherapy for prostate cancer Brachytherapy for prostate cancer Wills F, Hailey D Authors' objectives To review the effectiveness of brachytherapy for prostate cancer. Searching MEDLINE (1997 to Aug 1999, the Cochrane Library (latest version), Cancerlit (1997 to Aug 1999), EMBASE (1997 to April 1999), HealthSTAR (1992 to Aug 1999) and CINAHL (1997 to April 1999) were searched (search terms listed). In addition, the reference lists of retrieved articles were (...) searched. Information about prostate cancer and brachytherapy was also obtained by searching the World Wide Web. No language restrictions are reported. Study selection Study designs of evaluations included in the review Study designs comparing brachytherapy with other therapeutic approaches were preferred. Study designs reported in the review include: controlled trials, prospective and retrospective studies. Specific interventions included in the review Brachytherapy (a radiotherapy technique

DARE.1999

818. Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer

Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer Blue Cross and Blue Shield Association, Aronson N, Seidenfeld J Authors' objectives To assess the relative effectiveness (...) of alternative strategies for androgen suppression as treatment of advanced prostate cancer. There were three separate assessments within the review: 1. The relative effectiveness of the available methods for monotherapy (orchidectomy, luteinising hormone-releasing hormone (LHRH) agonists, and antiandrogens). 2. The effectiveness of combined androgen blockade versus monotherapy. 3. The effectiveness of immediate versus deferred androgen suppression. Searching MEDLINE, EMBASE, and Cancerlit were all searched

DARE.1999

819. A comprehensive review of prostate cancer brachytherapy: defining an optimal technique

A comprehensive review of prostate cancer brachytherapy: defining an optimal technique A comprehensive review of prostate cancer brachytherapy: defining an optimal technique A comprehensive review of prostate cancer brachytherapy: defining an optimal technique Vicini F A, Kini V R, Edmundson G, Gustafson G S, Stromberg J, Martinez A Authors' objectives To determine if an optimal method of implantation could be identified, and to compare and contrast techniques currently in use for brachytherapy (...) in the treatment of prostate cancer. Searching MEDLINE (January 1, 1985 to August 1, 1998) was searched for articles published in the English language. The MeSH terms used were 'prostatic neoplasms', 'prostatic neoplasms brachytherapy', 'prostatic neoplasms interstitial brachytherapy', and 1985 to 1998. Study selection Study designs of evaluations included in the review Any study that reported on prostate cancer treatment using brachytherapy and presented evaluable treatment results. Literature reviews were

DARE.1999

820. The utility of serial complete blood count monitoring in patients receiving radiation therapy for localized prostate cancer

The utility of serial complete blood count monitoring in patients receiving radiation therapy for localized prostate cancer The utility of serial complete blood count monitoring in patients receiving radiation therapy for localized prostate cancer The utility of serial complete blood count monitoring in patients receiving radiation therapy for localized prostate cancer Blank K R, Cascardi M A, Kao G D Record Status This is a critical abstract of an economic evaluation that meets the criteria (...) for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The health technology considered in the study was complete blood count (CBC), a weekly monitoring system for patients receiving definitive radiation therapy for prostate cancer. The technique measures white blood cells (WBCs), haemoglobin, and platelets, to estimate whether

NHS Economic Evaluation Database.1999